Holen Sie sich die Stockscreener-App
5.122
2.66%
-0.148
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Perspective Therapeutics (CATX) director awarded 50,000-share stock option grant - Stock Titan
Director at Perspective Therapeutics (CATX) awarded 50,000 stock options - Stock Titan
Director at Perspective Therapeutics (CATX) awarded 50K stock options - Stock Titan
Perspective Therapeutics (CATX) CAO receives 90,000-stock-option equity award - Stock Titan
Perspective Therapeutics (CATX) CMO receives 150,000 stock options as 2026 award - Stock Titan
CATX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CATX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CATX SEC FilingsPerspective Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Does Perspective Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn
Sectors Review: Is Olin Corporation in a long term uptrend2025 Trade Ideas & Precise Trade Entry Recommendations - baoquankhu1.vn
Take Profit: Does Perspective Therapeutics Inc stock have upside surprise potentialShort Setup & Stock Portfolio Risk Management - baoquankhu1.vn
Perspective Therapeutics (NASDAQ:CATX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Perspective Therapeutics (CATX) and Its Rivals Head to Head Survey - Defense World
349,323 Shares in Perspective Therapeutics, Inc. $CATX Purchased by Patient Square Capital LP - MarketBeat
CATXPerspective Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Perspective Therapeutics (NASDAQ:CATX) Coverage Initiated at Piper Sandler - Defense World
Radioligand Therapies Market Size, Share | Growth Report 2034 - Fortune Business Insights
Perspective Therapeutics (NASDAQ:CATX) Rating Increased to Strong-Buy at Piper Sandler - MarketBeat
Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 12.3%Still a Buy? - MarketBeat
Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 12.3% – Still a Buy? - Defense World
Piper Sandler initiates Perspective Therapeutics stock rating at overweight By Investing.com - Investing.com Nigeria
Perspective Therapeutics (CATX) Receives a Buy from JonesTrading - The Globe and Mail
This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
CATX Initiates Coverage with Overweight Rating by Piper Sandler - GuruFocus
Piper Sandler Initiates Coverage of Perspective Therapeutics (CATX) with Overweight Recommendation - Nasdaq
Piper Sandler initiates Perspective Therapeutics stock rating at overweight - Investing.com UK
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress - Insider Monkey
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else - Benzinga
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results - Bitget
Contrasting Perspective Therapeutics (CATX) and Its Peers - Defense World
Financial Review: Perspective Therapeutics (CATX) & Its Rivals - Defense World
How Perspective Therapeutics Inc. stock reacts to new regulations2025 Pullback Review & Long-Term Growth Portfolio Plans - mfd.ru
CATX Technical Analysis & Stock Price Forecast - Intellectia AI
CATX PE Ratio & Valuation, Is CATX Overvalued - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Icon (ICLR) and Perspective Therapeutics (CATX) - The Globe and Mail
Can Perspective Therapeutics Inc. lead its sector in growthDividend Hike & Low Drawdown Investment Ideas - mfd.ru
Will Perspective Therapeutics Inc. benefit from rising consumer demandJuly 2025 Patterns & Low Risk High Win Rate Stock Picks - mfd.ru
Perspective Therapeutics Outperforms Competitors in Key Metrics - National Today
Can Perspective Therapeutics Inc. expand into new marketsLayoff News & Safe Capital Investment Plans - mfd.ru
Activity Recap: Does Perspective Therapeutics Inc stock have upside surprise potentialExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn
Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed? - Yahoo Finance
Perspective Therapeutics Raises Capital to Advance Radiopharmaceutical Pipeline - TipRanks
Perspective Therapeutics Prices Approx. $175 Mln Offering Of Shares And Pre-Funded Warrants - Nasdaq
Perspective Therapeutics (CATX) Raises $175 Million Through Stoc - GuruFocus
Perspective Therapeutics shares rise after $175 million offering By Investing.com - Investing.com South Africa
Perspective Therapeutics shares rise after $175 million offering - Investing.com
Perspective Therapeutics jumps after $175 mln equity offering - TradingView
Perspective Therapeutics (CATX) Announces $175M Public Offering - GuruFocus
Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering - TipRanks
Perspective Therapeutics prices $175M equity offering; shares up - MSN
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - marketscreener.com
Perspective Therapeutics taps $175M stock sale to fund cancer radiopharma work - Stock Titan
Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX) - Defense World
Brokerages Set Perspective Therapeutics (NASDAQ:CATX) Target Price at $11.17 - Defense World
A Look At Perspective Therapeutics (CATX) Valuation After New VMT-α-NET Trial And Pipeline Updates - Yahoo Finance
2.76%
Kapitalisierung:
|
Volumen (24h):